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Analysis of Volatile Organic Compounds in the Exhaled
Breath for the Diagnosis of Lung Cancer
Peter J. Mazzone, MD, MPH, FRCPC, FCCP
Abstract: Volatile organic compounds are able to be detected in the
exhaled breath by a variety of sensing techniques. These volatiles
may be produced by cellular metabolic processes, or inhaled/ab-
sorbed from exogenous sources. Lung cancer cells may produce and
process these compounds different than normal cells. The differ-
ences may be detectable in the breath. The following manuscript will
review the evidence supporting the premise that a unique chemical
signature can be detected in the breath of patients with lung cancer,
discuss the results of studies using mass spectrometry and nonspe-
cific chemical sensing techniques to detect the unique lung cancer
signature, and speculate on the advancements that must occur to
develop a breath test accurate enough to be clinically useful.
Key Words: Breath test, Volatile organic compounds, Mass spec-
trometry, Diagnostic test.
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Lung cancer is a major public health problem in the UnitedStates and worldwide. In 2008 there will be an estimated
161,840 deaths from lung cancer in the United States.1 This
exceeds the number of deaths from breast, prostate, colon,
and pancreatic cancer combined.1 Despite the identification
of at risk individuals, screening studies using imaging and
sputum analysis have yet to demonstrate a reduction in lung
cancer specific mortality. Thus, lung cancer is frequently
diagnosed at an advanced stage when treatment is less effec-
tive. Currently, the diagnosis of lung cancer is made from a
biopsy taken of a lung nodule or mass found during the
evaluation of symptoms or as a result of unrelated imaging.
Advances in computed tomography (CT) imaging have led to
an epidemic of small lung nodules being detected. The
evaluation of these nodules is costly, typically requiring serial
imaging, and provoking undue anxiety. A simple to use,
inexpensive, noninvasive, and accurate lung cancer test
would be a major advance in the management of lung cancer
and the evaluation of lung nodules.
There is a growing literature on the analysis of volatile
organic compounds (VOCs) in the exhaled breath for the
diagnosis of lung cancer. A breath test that is capable of
accurately diagnosing early stage lung cancer has tremendous
potential utility as part of a screening or diagnostic algorithm,
and in the evaluation of small lung nodules. This manuscript
will outline evidence supporting the potential for develop-
ment of such a test, and speculate on the advances that need
to occur to make it a reality.
Volatile Organic Compounds in the Breath
Exhaled breath is largely composed of nitrogen, oxygen,
carbon dioxide, water, and inert gases. Trace components—
volatile substances that are generated in the body or absorbed
from the environment—present in the nmol/l–pmol/l (parts per
billion volume—parts per trillion volume) range make up the
rest of the breath. The exogenous volatiles are inhaled into and
absorbed through the lungs or absorbed through the skin. They
originate from many solvents and petroleum based products.
The endogenous volatiles are generated by the cellular biochem-
ical processes of the body. Thus, measurement of VOCs in the
breath can provide a window into the biochemical processes of
the body.
Several classes of VOCs can be measured in the ex-
haled breath (Table 1). These include saturated and unsatur-
ated hydrocarbons, oxygen-containing, sulfur-containing, and
nitrogen-containing compounds. Saturated hydrocarbons
(e.g., ethane, pentane, and aldehydes) are formed during lipid
peroxidation of fatty acid components of cell membranes,
triggered by reactive oxygen species (ROS). They are felt to
be markers of oxidative stress. Smaller quantities may be
produced by protein oxidation and colonic bacterial metabo-
lism. They have a low solubility in the blood and hence are
excreted in the breath within minutes of their formation.
Unsaturated hydrocarbons are also detected in the exhaled
breath. One example, isoprene, is formed along the meval-
onic pathway of cholesterol synthesis. Oxygen-containing
compounds such as acetone are found in the breath. Acetone
is produced by decarboxylation of acetoacetate which is
derived from lipolysis or lipid peroxidation. Sulfur containing
compounds found in the breath can be generated by incom-
plete metabolism of methionine in the transamination path-
way. Nitrogen containing compounds can be elevated in the
breath of subjects with liver impairment or uremia. The origin
of many endogenous VOCs is not known. Additional work
needs to be performed to learn about the important biochem-
ical pathways for all of the volatiles that can be detected.2
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The first report detailing the identification of VOCs in
the breath of healthy subjects was published in 1971. Ap-
proximately 250 separate VOCs were identified.3 More re-
cently, gas chromatography–mass spectrometry (GC-MS)
analysis of VOCs in the C4-C20 range in the exhaled breath
of 50 normal individuals found the average number of VOCs
was 204 per person. In total 3481 different VOCs were
identified with 27 common to all subjects.4 Others have
reported changes in the quantity of VOCs produced when
supplemental oxygen is administered to healthy subjects,5
differences in smokers versus nonsmokers,6 and differences
with age.7
Rationale for the Study of Breath VOCs in
Lung Cancer
For the pattern of breath VOCs of patients with lung
cancer to be unique, the biochemical processes that lead to
their generation or metabolism must be different in lung
cancer patients than in those without lung cancer.
The following are a few examples of differences in the
biochemical processes of lung cancer cells:
Y ROS are increased by cigarette smoke. The VOCs pro-
duced as a result of lipid peroxidation from these ROS
can be metabolized by cytochrome P450 (CYP) mixed
oxidase enzymes. Polycyclic aromatic hydrocarbons in
tobacco smoke may induce CYP enzymes. For example,
polymorphisms are present for the inducibility of CYP-
1A1. Easy inducibility seems to be more common in
individuals with lung cancer. The susceptible genotype
has been associated with higher disease recurrence rates
and lower survival rates.8 Thus, the activation of CYP
enzymes in individuals with lung cancer may accelerate
the degradation of VOCs that are produced as a result of
oxidative stress.
Y Adenosine monophosphate-activated protein kinase
(AMPK) is a key cellular energy sensor. When cells are
faced with energy stresses, such as in tumor microenvi-
ronments, AMPK functions to restore energy balance.
When active, AMPK functions to inhibit synthetic path-
ways and stimulate catabolic pathways in an effort to
restore levels of adenosine triphosphate.9 Activated
AMPK leads to decreased lipogenesis and increased
fatty acid oxidation, which can alter the production of
VOCs. AMPK activation has been reported in tumor
xenografts.10 LKB1, the upstream kinase of AMPK, is a
tumor suppressor known to be mutated in Peutz–Jeghers
syndrome. Mutations in LKB1 have also been reported
in 30–50% of lung large cell and adenocarcinoma cell
lines.11–13 Fibronectin, a tumor matrix protein, has been
found to inactivate LKB1/AMPK signaling pathways.14
Differences in AMPK activation may lead to differences
in the production or metabolism of VOCs.
Y The expression of the antioxidants manganese superox-
ide dismutase and catalase is different in lung cancer
tissue than in normal tissue.15 This may influence the
VOCs identified in the breath.
Other support for this concept exists in the literature:
Y One study investigated the production of volatile com-
pounds from the head-space gas of two cancer cells lines
(SK-MES, CALU-1) in vitro using selected ion flow
tube mass spectrometry (SIFT-MS). They found that
acetaldehyde was produced at concentrations above
physiologic. The concentration of acetaldehyde was pro-
portional to the number of cells in the medium.16
Y Another study has looked at the origin, distribution, and
metabolism of exhaled volatiles by comparing blood
volatiles to those in the breath of 10 healthy controls and
10 individuals with stage I lung cancer. They found 25
total compounds that had previously been reported in the
breath of lung cancer patients. High levels of hexanal
and heptanal were measured in those with lung cancer
but not in healthy controls. These compounds were also
detected in the breath of the subjects with lung cancer
but not the breath of the controls. They concluded that
the VOCs in the breath originate in the blood.17
Y Other investigators studied VOCs from the headspace of
lung cancer cell media. VOCs from the culture medium
of lung cancer cells differed from virgin culture medium
and differed from that of control cell cultures (bronchial
epithelial cells, tastebud cells, osteogenic cells, and
lipocytes).18
The above rationale and support has stimulated inves-
tigators to analyze patterns of breath VOCs to determine their
potential as a diagnostic test for lung cancer. Two groups of
sensor systems have been used for this purpose—mass spec-
trometry systems and nonspecific gaseous chemical sensing
devices.
Studies Using Mass Spectrometry
Several studies have compared patterns of VOCs in
lung cancer patients to various control groups using mass
spectrometry (Table 2). Two of the most recent studies are
described here.
TABLE 1. Classes of Volatile Organic Compounds in the Breath
Class of VOC Example Example of Mechanism of Production
Saturated hydrocarbons Ethane, pentane, aldehydes Lipid peroxidation of fatty acid components of cell membranes–triggered by
reactive oxygen species
Unsaturated hydrocarbons Isoprene Mevalonic pathway of cholesterol synthesis
Oxygen-containing Acetone Decarboxylation of acetoacetate from lipolysis or lipid peroxidation
Sulfur-containing Ethyl mercaptane, dimethylsulfide Incomplete metabolism of methionine
Nitrogen-containing Dimethylamine, ammonia Elevated in liver impairment and uremia
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In 2005, a study was reported comparing concentra-
tions of 13 VOCs (seven aliphatic and six aromatic com-
pounds) from the breath of early stage non-small cell lung
cancer patients (36 subjects) with asymptomatic smokers (35
subjects), control nonsmokers (50 subjects), and subjects with
mild to moderate chronic obstructive pulmonary disease
(COPD) (25 subjects). In addition, samples were collected in
26 subjects both before and after resection of their tumor.
After 60 minutes of rest, study subjects performed a single
slow vital capacity breath through a one-way valve into a
Teflon bulb that trapped the final 150 ml of exhaled breath.
Exhaled VOCs were extracted by means of a solid-phase
microextraction fiber then analyzed by GC-MS. Levels of the
studied VOCs were higher in the cancer group, COPD group,
and asymptomatic smoker group than in the nonsmoker
controls and ambient air. Multinomial logistic regression was
used to predict the subject category from the VOC concen-
trations. There was an overall accuracy of 82% with a
sensitivity and specificity for lung cancer of 72.2 and 93.6%,
respectively. The concentration of only two VOCs (isoprene
and decane) decreased significantly after resection. This re-
port added to the literature by trying to standardize breath
collection techniques, enrolling early stage lung cancer pa-
tients, and comparing them to controls with otherwise similar
characteristics.25
In 2007, results of breath analysis from 193 untreated
lung cancer patients and 211 control subjects participating in
a lung cancer screening trial who had negative chest CT scans
were reported. There was no difference in age, sex, or
smoking history between the two groups. In addition, 80
postlung cancer resection patients were studied. All subjects
breathed normally for 2 minutes into a breath collection
device designed to sample alveolar air. The VOCs from 1
liter of alveolar air and a separate 1 liter of ambient air were
collected on sorbent traps and analyzed via automated ther-
mal desorption with GC-MS. The subjects were divided in a
2:1 fashion into a training set and prediction set. Multiple
pattern recognition statistical techniques were used to analyze
the results with a fuzzy logic model proving to have the best
discriminatory capabilities. With this model 16 VOCs,
mainly alkane derivatives, were found to be statistically
different between the groups. Alveolar gradients were calcu-
lated for these VOCs. In general, they were lower in the
breath of cancer subjects than controls. Fuzzy logic calcu-
lated typicality scores for cancer and control groups in the
training set based on the VOC levels and interactions. These
were applied to the prediction set. If a subject’s typicality
score was closer to the cancer group then the test was labeled
as suggesting cancer was present. Using this method the test
had a sensitivity of 84.6% and specificity of 80% with an area
under the curve of 0.88. The results were validated using a
leave-one-out model that showed a sensitivity of 80% and
specificity of 81% for an area under the curve of 0.88. The
robustness of the results was suggested by finding similar
results from 20 iterations of the analysis using randomly
chosen training and prediction sets. There was no difference
in the results across stages 1–4. Smoking status did not affect
the results. In the 80 subjects who had completed resection
for lung cancer the test was positive for lung cancer in 77
(96.3%) leading the authors to speculate that the VOCs were
coming from other tissues that shared metabolic changes
suggestive of cancer. In 45 subjects who were eliminated
from the main group (31 with primary or recurrent lung
cancer, 14 with metastatic cancer, mesothelioma, or a
benign tumor), all 45 were felt to be positive for cancer on
the breath test.26
The results of the GC-MS studies are promising but the
accuracies are not yet high enough to be clinically useful. The
benefits of the GC-MS systems are that they are very sensi-
tive and can detect specific VOCs and measure their concen-
trations. The downside is that the systems are expensive, they
require some expertise to use, and the breath contents need to
be captured then transported to the devices. Thus, these
systems are not ideal as point-of-care tests.








in Model Model Accuracy Validation Accuracy
Gordon et al.19 1985 12 17 3 93% NA
O’Neill et al.20 1988 8 0 9 NA NA
Preti 21 1988 10 16 2 NA NA
Phillips et al.22 1999 60 48 22 81.50% 71.7% sens, 66.7% spp*
Phillips et al.23 2003 67 132 9 89.6% sens, 82.9% spp vs. healthy controls,
37.4% spp in lung disease controls
85.2% sens, 80.5% spp vs.
healthy controls†
Corradi et al.24 2003 14 43 NA NA NA
Poli et al.25 2005 36 110 13 NA 72.2% sens, 93.6% spp
Phillips et al.26 2007 193 211 16 86.7% sens, 79.4% spp 84.6% sens, 80% spp
Chen et al.18 2007 29 20 11 NA 86.2% sens, 69.2% spp
Wehinger et al.27 2007 17 170 2 NA 54% sens, 99% spp‡
*Leave one out methodology used for validation (not an additional data set).
†Volatile organic compounds of interest determined prior to testing (not a separate model and validation set).
‡Relevant volatile organic compounds chosen from whole group, with validation performed by splitting the same group into model and test groups with multiple iterations (not
an additional data set).
Sens, sensitivity; spp, specificity.
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Studies Using Non-Specific Gaseous Chemical
Sensing Devices
Recently, gaseous chemical sensing and identification
devices have been developed that are able to detect a single
(or patterns of) odorant molecule(s) such as VOCs. These
devices have used a variety of sensor arrays including con-
ductive polymers, nonconductive polymer/carbon black com-
posites, metal oxide semiconductors, fluorescent dye/polymer
systems, quartz microbalance sensors coated with metallo-
porphyrins, polymer coated surface acoustic wave devices,
and chemoresponsive dyes. The premise with most of these
systems is that absorption of gases onto the sensor system
causes a change in the conductivity, mass, vibration, or color
of the sensor, thus altering its’ output. The systems generally
consist of an array of sensors, which can be tuned to their
task. The composite output of the array requires multivariate
statistical techniques to analyze the patterns of output pro-
duced (a “smellprint”). The sensitivities of these devices to
various chemical groups and concentrations vary with the
particular sensing technology. Some report sensitivities in the
parts per billion range. A few of these sensors have been
studied as diagnostic tests for lung cancer (Table 3).
The first report of the use of a gaseous chemical sensing
device for the diagnosis of lung cancer appeared in 2003. The
authors used a quartz microbalance sensor system. The output
of these sensors is the variation of oscillating frequency of the
sensor. As molecules adsorb to the surface of the sensor,
the mass of the sensor changes, leading to variation in the
oscillating frequency. The sensors are given different chem-
ical sensitivities by coating their surface with chemicals that
bind to VOCs. In this study, eight different metalloporphyrins
were used to give the quartz sensors different chemical
sensitivities. The study population included 35 individuals
with lung cancer, nine with previously resected lung cancer
(two of which were studied before resection as well), and 18
healthy controls. Analysis of this output was reported to show
near 100% correct classification of lung cancer and 94%
classification of healthy controls. The model that was devel-
oped was not validated on additional patient groups.28
Another report of the use of a gaseous chemical sensing
device to diagnose lung cancer was published in 2005. This
study used a carbon polymer sensor system with 32 separate
sensors. The system’s output is the reversible change in
resistance across each sensor as various chemicals adsorb to
the surface. The chemical sensitivity of each sensor is unique
because of the chemical diversity of the sensor materials.
This study was performed in two phases, a training phase and
a validation phase. In each phase subjects inhaled filtered air
then exhaled from total lung capacity into a Mylar bag. Each
sample was analyzed five times. In the training phase, the
study population included 14 lung cancer patients, 19 sub-
jects with -1 antitrypsin deficiency, six with chronic beryl-
lium disease, two with COPD, and 20 healthy controls.
Analysis suggested that the sensor output from lung cancer
subjects was distinguishable from healthy controls whereas
the output from other disease groups was not. This did not
vary by cell type, stage of cancer, smoking status, or forced
expiratory volume in 1 second. A support vector machine
algorithm was created from this training group and applied to
a separate population of subjects for validation. In this group
there were 14 lung cancer patients (six with small cell
carcinoma), 12 with COPD, two with resected lung cancer,
11 with asthma, seven with pulmonary hypertension, and 30
healthy volunteers. The model identified 85% of the samples
accurately for an overall sensitivity of 71.4% and specificity
of 91.9%.30
A study was published in 2007 using colorimetric
sensor array technology. The sensor used by this system had
36 spots composed of different chemically sensitive com-
pounds (e.g., metalloporphyrins) impregnated on a disposable
cartridge (Figure 1). The colors of these spots change based
on the chemicals they come in contact with. In this study,
individuals with lung cancer, other lung diseases, and healthy
controls performed tidal breathing of room air for 12 minutes.
During this time they exhaled into a device designed to draw
their breath across a colorimetric sensor array. A scanner
documented color changes occurring on the array over time.
The color changes for each individual were converted into a
numerical vector. The vectors were analyzed statistically to
determine if lung cancer could be predicted from the sensor
responses. 143 individuals participated in the study, 49 with
non-small cell lung cancer, 18 COPD, 15 idiopathic pulmo-
nary fibrosis, 20 pulmonary arterial hypertension, 20 sarcoid-
osis, and 21 healthy controls. A prediction model was devel-
oped using observations from 70% of the subjects. This
model was able to predict the presence of lung cancer in the
remaining 30% of the subjects with a sensitivity of 73.3% and
specificity of 72.4%. There was no difference based on age,
sex, smoking status, or stage of lung cancer. Twenty-one
subjects with small indeterminate lung nodules were studied,
one of which was lung cancer. The sensitivity of the model
was 100% with a specificity of 60% when applied to this
group.31
TABLE 3. Studies of Gaseous Chemical Sensing Devices for the Evaluation of Breath VOCs in Lung Cancer
Author Year Cancer Subjects Control Subjects Sensor System Model Accuracy Validation Accuracy
DiNatale et al.28 2003 35 18 Quartz microbalance NA 90.3%*
Chen et al.29 2005 5 5 Surface acoustic wave NA 80%
Machado et al.30 2005 28 109 Carbon-polymer array 71.6% sens 71.4%, spp 91.9%
Mazzone et al.31 2007 49 94 Colorimetric sensor array 85.9% sens 73.3%, spp 72.4%
*Leave one out methodology used for validation (not an additional data set).
Sens, sensitivity; spp, specificity.
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The benefits of the gaseous chemical sensing devices
over GC-MS are that they are relatively inexpensive, and
easy to use for point-of-care testing as they are made of
reusable or disposable sensors. They have been criticized for
their lack of ability to identify the specific chemical com-
pounds within the breath that are different between those with
and without lung cancer. In addition they may not be sensi-
tive enough to detect all of the potentially important VOCs in
the breath.
How Accurate Does the Test Need to Be?
The accuracy of the breath test required for it to be
clinically useful depends on the purpose of the test. A breath
diagnostic for lung cancer could be used as part of a lung
cancer screening program or in the diagnosis of indeterminate
lung nodules. If used as part of a screening program you
would like the test to raise the probability of malignancy in
the population that receives a positive test high enough to
avoid many CT scans and unnecessary biopsies while ensur-
ing that very few individuals with lung cancer are missed. For
example, in CT screening trials of high risk individuals the
prevalence of malignancy (i.e., on the initial screen) is ap-
proximately 1.5%. Thus for every 200 CT scans, three people
are diagnosed with lung cancer and 197 additional scans are
performed. A breath test would be useful if it could raise the
probability of lung cancer in anyone having a CT scan so that
fewer CT scans would be performed in those without lung
cancer, yet allow the screening program to miss very few
with lung cancer. To have one cancer identified for every 10
scans performed the specificity of the breath test would need
to be between 85 and 90%. To ensure that only one of every
1000 patients with a negative breath test has lung cancer (and
thus could have benefited from having a CT scan) the sensi-
tivity of the test must approach 95%. For the incidence
screens (i.e., the yearly follow-up chest CT scans), only 0.5%
of at risk subjects are found to have lung cancer. Thus only
one of 200 CT scans performed finds lung cancer. To have
one cancer for every 10 scans performed on the incidence
screen the specificity of the test must now exceed 95%. For
only one of every 1000 negative breath test results to occur in
a patient with lung cancer, the sensitivity of the test must be
85% or better (Tables 4 and 5).
If the test is used to diagnose lung cancer from inde-
terminate lung nodules you would like the test to be accurate
enough to influence clinical decisions for a wide range of
patients (Table 6). For example, for a given patient you might
suggest resection of the lung nodule if the probability of
malignancy was 90% or greater and follow-up with serial
imaging if the probability of malignancy was less than 10%.
TABLE 4. Test Characteristics for the Prevalence Screen of a
Lung Cancer Screening Program
Sensitivity Specificity LR PPV NPV
95 95 19 22.4 99.92
90 9.5 12.6 99.92
85 6.3 8.8 99.91
90 95 18 21.5 99.84
90 9 12.1 99.83
85 6 8.4 99.82
85 95 17 20.6 99.76
90 8.5 11.5 99.75
85 5.7 7.9 99.73
80 80 4 5.7 99.6
CT screening studies of high risk individuals (e.g. smokers over age 55) have found
a prevalence of lung cancer of approximately 1.5% (i.e. 67 patients have CT scans for
every 1 cancer diagnosed on the initial screen). To raise the prevalence in those who
would require imaging to 10% or greater (i.e. 10 patients would have a CT scan for
every one cancer diagnosed on the initial screen) a breath test would have to have a
specificity of near 90%. A sensitivity of at least 90% would mean most with lung cancer
will not be missed.
LR, likelihood ratio; PPV, positive predictive value; NPV, negative predictive
value.
TABLE 5. Test Characteristics for the Incidence Screen of a
Lung Cancer Screening Program
Sensitivity Specificity LR PPV NPV
95 95 19 8.7 99.97
90 9.5 4.6 99.97
85 6.3 3.1 99.97
90 95 18 8.3 99.95
90 9 4.3 99.94
85 6 2.9 99.94
85 95 17 7.9 99.92
90 8.5 4.1 99.92
85 5.7 2.8 99.91
80 80 4 2.0 99.87
CT screening studies of high risk individuals have found an incidence of lung
cancer of approximately 0.5% (i.e. 200 patients have CT scans for every one cancer
diagnosed on yearly follow-up screens). To raise the incidence in those who would
require imaging to close to 10% (i.e. 10 patients would have a CT scan for every one
cancer diagnosed on yearly follow-up screens) a breath test would have to have a
specificity of greater than 95%. A sensitivity of at least 90% would mean most with lung
cancer will not be missed.
LR, likelihood ratio; PPV, positive predictive value; NPV, negative predictive
value.
FIGURE 1. Example of colorimetric sensor used in Ref. 31.
Chemoresponsive dyes are impregnated on the disposable
cartridge. The dye colors change based on the chemicals
that adhere to them.
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Prebreath test probabilities of malignancy would be deter-
mined using traditional clinical and radiographic features of
the nodule. A breath test that is 95% sensitive and specific
could raise the probability of malignancy to greater than 90%
if the pretest probability was 32.1% or greater, whereas the
pretest probability would need to be at least 69.2% to have a
post-test probability of 90% or greater if the test was only
80% sensitive and specific. Similarly, to lower the probability
of malignancy to 10% or less the pretest probability could be
67.7% or lower for a test that is 95% sensitive and specific
but would have to be 30.7% or lower if the test was just 80%
sensitive and specific.
How Accurate Can the Test Be?
An unusual line of evidence has suggested that breath
analysis can be improved to the point of clinical utility. A
group of investigators studied the ability of dogs to detect
lung cancer. They enrolled 55 patients with lung cancer and
83 healthy volunteers in their study. The dogs were trained to
identify the samples from cancer patients by using 27 of the
lung cancer patients’ samples and 66 of the healthy controls.
In double-blinded testing using the remaining subjects sam-
ples, the dogs were able to detect lung cancer with a 99%
sensitivity and specificity.32
How to Improve the Test Accuracy
Technical and procedural advances will help to im-
prove and clarify the accuracy of breath testing for lung
cancer:
Y The unique pattern of VOCs in the breath of lung cancer
patients needs to be further characterized. Studies using
MS have used different VOC patterns for their models
(Table 2). Advances in the ability of chemical sensing
devices to detect VOCs at lower concentrations in near
real-time is occurring.33–35
Y Information about the unique pattern of VOCs in the
breath of lung cancer patients, gathered from advanced
sensing systems, can be used to refine point-of-care
testing devices.
Y The pattern of breath VOCs for different lung cancer
histologies and other tumor characteristics should be
clarified.
Y Breath collection methods should be standardized so
that the most important portion of the breath can be
identified and a consistent sample of that portion is easy
to obtain (e.g., alveolar breath).
Y A standard approach to controlling for ambient VOCs
should be adopted.
Y Testing of the devices that are developed should occur in
populations similar to those in whom the test will be
applied.
Summary
The analysis of VOCs in the exhaled breath of individ-
uals with lung cancer has the potential to develop into a
useful investigational and clinical tool. Advances in analytic
techniques will allow us to more accurately identify the
unique constituents of the breath. This could translate into a
better understanding of the pathobiology of lung cancer while
assisting with its’ clinical management.
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TABLE 6. Test Characteristics for the Diagnosis of Lung
Cancer from Indeterminate Lung Nodules
Sensitivity Specificity PoTP 90% PoTP 10%
95 95 32.1 67.7
90 90 50 50
85 85 61.2 38.8
80 80 69.2 30.7
When evaluating a patient with a lung nodule, clinical and radiographic features are
used to predict the likelihood of malignancy in the nodule. An adjuvant test would be
most useful if it raised the probability of malignancy to the point where additional
testing would not be needed (e.g. 90%) or lowered the probability of malignancy to the
point where follow-up alone was appropriate (e.g. 10%). The above table shows the
pretest probability necessary to reach these thresholds for different sensitivities and
specificities of the test. For example, to raise the post-test probability to 90% or greater
with a test that is 95% sensitive and specific the pretest probability must be at least
32.1%, whereas the pretest probability would need to be at least 69.2% to have a
post-test probability of 90% or greater if the test was only 80% sensitive and specific.
Similarly, to lower the probability of malignancy to 10% or less after testing, the pretest
probability must be 67.7% or less for a test that is 95% sensitive and specific. For a test
that is 80% sensitive and specific to lower the probability of malignancy to below 10%
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